| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.3 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |